AKT1 and cancer: Activation of the phosphatidylinositide‐3‐kinase (PI3K)/serine/threonine‐specific protein kinase (AKT)/mammalian target of rapamycin (mTOR) pathway has been implicated in the growth and progression of various cancers, as well as resistance to standard anticancer therapies 2.